Bobby Gaspar
Chief Executive Officer at ORCHARD THERAPEUTICS PLC
Profile
Dr. Bobby Gaspar is a Chief Executive Officer & Director at Orchard Therapeutics (Europe) Ltd., a Chief Executive Officer at Orchard Therapeutics Plc and a Chief Executive Officer at Orchard Therapeutics North America.
He is on the Board of Directors at Alliance for Regenerative Medicine, Centre For Research In Rare Diseases In Children and Orchard Therapeutics (Europe) Ltd.
Dr. Gaspar was previously employed as a Professor by UCL Institute of Child Health.
He received his graduate degree from King's College London and a doctorate degree from the University College London.
Bobby Gaspar active positions
Companies | Position | Start |
---|---|---|
ORCHARD THERAPEUTICS PLC | Chief Executive Officer | 2020-03-17 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Founder | 2015-01-01 |
Centre For Research In Rare Diseases In Children | Director/Board Member | 2017-12-31 |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Director/Board Member | 2020-12-31 |
Orchard Therapeutics North America
Orchard Therapeutics North America BiotechnologyHealth Technology Part of Orchard Therapeutics Plc, Orchard Therapeutics North America provides biotechnology research services. The company is based in Boston, MA. The CEO of the company is Bobby Gaspar. | Chief Executive Officer | - |
Former positions of Bobby Gaspar
Companies | Position | End |
---|---|---|
UCL Institute of Child Health | Corporate Officer/Principal | 2020-02-29 |
Training of Bobby Gaspar
University College London | Doctorate Degree |
King's College London | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 6 |
---|---|
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
UCL Institute of Child Health | |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
Centre For Research In Rare Diseases In Children | |
Orchard Therapeutics North America
Orchard Therapeutics North America BiotechnologyHealth Technology Part of Orchard Therapeutics Plc, Orchard Therapeutics North America provides biotechnology research services. The company is based in Boston, MA. The CEO of the company is Bobby Gaspar. | Health Technology |
- Stock Market
- Insiders
- Bobby Gaspar